229 related articles for article (PubMed ID: 18682720)
1. Circulating endothelial cells as biomarkers of prostate cancer.
Georgiou HD; Namdarian B; Corcoran NM; Costello AJ; Hovens CM
Nat Clin Pract Urol; 2008 Aug; 5(8):445-54. PubMed ID: 18682720
[TBL] [Abstract][Full Text] [Related]
2. Circulating endothelial cells as biomarkers in clinical oncology.
Mancuso P; Bertolini F
Microvasc Res; 2010 May; 79(3):224-8. PubMed ID: 20176038
[TBL] [Abstract][Full Text] [Related]
3. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers.
Blann AD; Balakrishnan B; Shantsila E; Ryan P; Lip GY
Prostate; 2011 Jul; 71(10):1047-53. PubMed ID: 21557269
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology.
Bertolini F
Breast; 2009 Oct; 18 Suppl 3():S48-50. PubMed ID: 19914542
[TBL] [Abstract][Full Text] [Related]
5. Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers.
Reeves F; Sapre N; Corcoran N; Hovens C
Biomark Med; 2013 Dec; 7(6):879-91. PubMed ID: 24266820
[TBL] [Abstract][Full Text] [Related]
6. Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction.
Wu H; Chen H; Hu PC
Clin Lab; 2007; 53(5-6):285-95. PubMed ID: 17605403
[TBL] [Abstract][Full Text] [Related]
7. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy.
Dome B; Timar J; Ladanyi A; Paku S; Renyi-Vamos F; Klepetko W; Lang G; Dome P; Bogos K; Tovari J
Crit Rev Oncol Hematol; 2009 Feb; 69(2):108-24. PubMed ID: 18768327
[TBL] [Abstract][Full Text] [Related]
8. The multifaceted circulating endothelial cell in cancer: towards marker and target identification.
Bertolini F; Shaked Y; Mancuso P; Kerbel RS
Nat Rev Cancer; 2006 Nov; 6(11):835-45. PubMed ID: 17036040
[TBL] [Abstract][Full Text] [Related]
9. Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.
Smirnov DA; Foulk BW; Doyle GV; Connelly MC; Terstappen LW; O'Hara SM
Cancer Res; 2006 Mar; 66(6):2918-22. PubMed ID: 16540638
[TBL] [Abstract][Full Text] [Related]
10. [Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].
Farace F; Bidart JM
Bull Cancer; 2007 Jul; 94 Spec No():S254-9. PubMed ID: 17846012
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer.
Goodale D; Phay C; Brown W; Gray-Statchuk L; Furlong P; Lock M; Chin-Yee I; Keeney M; Allan AL
Cytometry B Clin Cytom; 2009 Mar; 76(2):107-17. PubMed ID: 18727054
[TBL] [Abstract][Full Text] [Related]
12. Circulating endothelial cells: markers of vascular dysfunction.
Goon PK; Boos CJ; Lip GY
Clin Lab; 2005; 51(9-10):531-8. PubMed ID: 16285476
[TBL] [Abstract][Full Text] [Related]
13. [Circulating endothelial cells(CECs), circulating endothelial progenitors (CEPs)].
Ueno T
Nihon Rinsho; 2012 Sep; 70 Suppl 7():464-9. PubMed ID: 23350443
[No Abstract] [Full Text] [Related]
14. Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma.
Tan KV; Namdarian B; Costello AJ; Hovens CM
Urol Oncol; 2011; 29(3):237-43. PubMed ID: 19914100
[TBL] [Abstract][Full Text] [Related]
15. Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma.
Namdarian B; Tan KV; Fankhauser MJ; Nguyen TT; Corcoran NM; Costello AJ; Hovens CM
BJU Int; 2010 Oct; 106(7):1081-7. PubMed ID: 20201835
[TBL] [Abstract][Full Text] [Related]
16. Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease.
Dome B; Dobos J; Tovari J; Paku S; Kovacs G; Ostoros G; Timar J
Cytometry A; 2008 Mar; 73(3):186-93. PubMed ID: 18000872
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells.
Bertolini F
Cancer Metastasis Rev; 2008 Mar; 27(1):95-101. PubMed ID: 18066648
[TBL] [Abstract][Full Text] [Related]
18. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
Saad F; Pantel K
Future Oncol; 2012 Mar; 8(3):321-31. PubMed ID: 22409467
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.
Massard C; Borget I; Le Deley MC; Taylor M; Gomez-Roca C; Soria JC; Farace F
Eur J Cancer; 2012 Jun; 48(9):1354-62. PubMed ID: 22370181
[TBL] [Abstract][Full Text] [Related]
20. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer.
Bogos K; Renyi-Vamos F; Dobos J; Kenessey I; Tovari J; Timar J; Strausz J; Ostoros G; Klepetko W; Ankersmit HJ; Lang G; Hoda MA; Nierlich P; Dome B
Clin Cancer Res; 2009 Mar; 15(5):1741-6. PubMed ID: 19240177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
